Concordance of survival in family members with prostate cancer.

PURPOSE Several earlier studies have assessed survival in prostate cancer based on familial risk of this disease. As a novel concept, we posit that factors governing survival in prostate cancer are likely to be different from those governing risk of prostate cancer. To prove this, we searched for familial clustering of survival (ie, concordance of survival among family members). PATIENTS AND METHODS We used the nationwide Swedish Family-Cancer Database to estimate hazard rates (HRs) for cause-specific and overall survival in invasive prostate cancer. HRs show the probability of death in the study group compared with the reference group. The study covered 610 sons of affected fathers with median follow-up times for survival ranging from 34 to 76 months. RESULTS When the survival in sons was analyzed according to the fathers' length of survival, there was a concordance of prognosis; the HR was 0.62 for sons whose fathers had survived longer than 59 months, compared with sons whose fathers had survived fewer than 24 months (P for trend, .02). On a continuous scale, the sons' survival increased almost linearly with the fathers' survival time. When the analysis was reversed and HRs were derived for fathers, the concordance of good and poor survival remained. CONCLUSION The results are consistent in showing that both good and poor survival in prostate cancer aggregate in families. Genetic factors are likely to contribute to the results, which provide the first challenging population-level evidence on heritability in prognosis of prostate cancer.

[1]  Asta Försti,et al.  Survival in breast cancer is familial , 2008, Breast Cancer Research and Treatment.

[2]  T. Rebbeck,et al.  Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. , 2007, The Journal of urology.

[3]  K. Czene,et al.  Is breast cancer prognosis inherited? , 2007, Breast Cancer Research.

[4]  Thorunn Rafnar,et al.  Prostate cancer progression and survival in BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[5]  J. Massagué,et al.  Genetic determinants of cancer metastasis , 2007, Nature Reviews Genetics.

[6]  K. Hemminki,et al.  The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence , 2006, Hereditary cancer in clinical practice.

[7]  W. Catalona,et al.  Characteristics of patients with familial versus sporadic prostate cancer. , 2006, The Journal of urology.

[8]  M. Blute,et al.  Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. , 2006, The Journal of urology.

[9]  K. Watabe,et al.  The role of tumor metastasis suppressors in cancers of breast and prostate. , 2006, Frontiers in bioscience : a journal and virtual library.

[10]  J. Ciezki,et al.  Aggressiveness of familial prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. H. van der Kwast,et al.  Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. , 2006, The Journal of urology.

[12]  E. Giovannucci,et al.  Role of diet in prostate cancer development and progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Hemminki,et al.  Familial risk of cancer shortly after diagnosis of the first familial tumor. , 2005, Journal of the National Cancer Institute.

[14]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[15]  E. Sacco,et al.  Familial and hereditary prostate cancer by definition in an italian surgical series: clinical features and outcome. , 2005, European urology.

[16]  J. Brooks,et al.  Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy. , 2005, Urology.

[17]  K. Hemminki,et al.  Prostate cancer screening, changing age‐specific incidence trends and implications on familial risk , 2005, International journal of cancer.

[18]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[19]  A. Loktionov.  Common gene polymorphisms, cancer progression and prognosis. , 2004, Cancer letters.

[20]  M. Rosén,et al.  Cancer Survival in Sweden 1960–1998 Developments Across Four Decades , 2003, Acta oncologica.

[21]  Henrik Grönberg,et al.  Prostate cancer epidemiology , 2003, The Lancet.

[22]  William C Hahn,et al.  Rules for making human tumor cells. , 2002, The New England journal of medicine.

[23]  T. Rebbeck.  Inherited genotype and prostate cancer outcomes. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  H. Grönberg,et al.  No difference in survival between sporadic, familial and hereditary prostate cancer. , 1998, British journal of urology.

[25]  J. Moul,et al.  Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. , 1998, Urology.

[26]  J. Witte,et al.  Familial prostate cancer: a different disease? , 1997, The Journal of urology.

[27]  J. Witte,et al.  Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Greenland.  Dose‐Response and Trend Analysis in Epidemiology: Alternatives to Categorical Analysis , 1995, Epidemiology.

[29]  John T. Wei,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.

[30]  K. Hemminki,et al.  The nation-wide Swedish family-cancer database--updated structure and familial rates. , 2001, Acta oncologica.